Advertisement

Pembrolizumab vs Ipilimumab in Advanced Melanoma: Long-Term Follow-up
Posted: 07/25/2023 | By: Sarah Campen, PharmD

A 7-year follow-up of the KEYNOTE-006 trial, published by Robert et al in the Journal of Clinical Oncology, tracked outcomes among patients with advanced melanoma who had received treatment with either pembrolizumab or ipilimumab.

Question 1 of 5

Which dosing option was NOT offered in the KEYNOTE-006 study?

Choose 1

A
Intravenous pembrolizumab at 10 mg/kg every 3 weeks for up to 24 months
B
Intravenous ipilimumab at 3 mg/kg every 3 weeks for four doses
C
Intravenous pembrolizumab at 10 mg/kg every 2 weeks for up to 24 months
D
Intravenous ipilimumab at 10 mg/kg every 3 weeks for four doses

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage